-
Views
-
Cite
Cite
Stéphanie Raymond, Anne Maillard, Corinne Amiel, Gilles Peytavin, Mary Anne Trabaud, Delphine Desbois, Pantxika Bellecave, Constance Delaugerre, Cathia Soulie, Anne Geneviève Marcelin, Diane Descamps, Jacques Izopet, on behalf the ANRS AC11 Resistance Study Group, S. Reigadas, P. Bellecave, P. Pinson-Recordon, H. Fleury, B. Masquelier, A. Signori-Schmuck, P. Morand, L. Bocket, L. Mouna, P. André, J. C. Tardy, M. A. Trabaud, D. Descamps, C. Charpentier, G. Peytavin, F. Brun-Vézinet, S. Haim-Boukobza, A. M. Roques, C. Soulié, S. Lambert-Niclot, I. Malet, M. Wirden, S. Fourati, A. G. Marcelin, V. Calvez, P. Flandre, L. Assoumou, D. Costagliola, L. Morand-Joubert, C. Delaugerre, V. Schneider, C. Amiel, G. Giraudeau, A. Maillard, F. Nicot, J. Izopet, on behalf the ANRS AC11 Resistance Study Group, Virological failure of patients on maraviroc-based antiretroviral therapy, Journal of Antimicrobial Chemotherapy, Volume 70, Issue 6, June 2015, Pages 1858–1864, https://doi.org/10.1093/jac/dkv026
Close - Share Icon Share
Abstract
Virological failure (VF) in patients on maraviroc-based treatment has been associated with altered HIV tropism and resistance to maraviroc. This multicentre study aimed to characterize VF in patients treated with maraviroc.
We analysed 27 patients whose treatment failed between 2008 and 2011. They had been screened for HIV tropism before maraviroc initiation using population-based V3 genotyping. HIV-1 tropism and resistance of R5 viruses to maraviroc at VF and at baseline were determined retrospectively using an ultrasensitive recombinant virus assay (RVA).
Viruses from 27 patients given maraviroc on the basis of the R5 genotype were characterized at the time of treatment failure. The RVA indicated that 12 patients harboured CXCR4-using viruses and 15 (56%) had pure R5 viruses at failure. One-third of those harbouring CXCR4-using viruses (4/12) were infected with R5X4/X4 viruses according to the RVA before maraviroc initiation. We analysed the phenotypic resistance to maraviroc of four patients harbouring R5 viruses at failure; two harboured viruses whose maximum percentage inhibition was reduced by 65%–90%, while the other two were infected with susceptible viruses. All patients had effective concentrations of drugs.
Half of the maraviroc-treated patients who experienced VF harboured CXCR4-using viruses at failure, one-third of them were detected by a phenotypic method before maraviroc initiation. Phenotypic assessment of R5 virus resistance to CCR5 antagonists at failure could help optimize antiretroviral therapy.
